Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection

Combination Antifungal Therapy for Invasive Aspergillosis

(2015) Kieren A. Marr et al.   ANNALS OF INTERNAL MEDICINE

Antifungal Combination Therapy for Invasive Aspergillosis

(2014) A. Martin-Pena et al.   CLINICAL INFECTIOUS DISEASES

Differences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal Amphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic Aspergillus flavus Infections

(2011) J. A. Olson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Liposomal Amphotericin B and Echinocandins as Monotherapy or Sequential or Concomitant Therapy in Murine Disseminated and Pulmonary Aspergillus fumigatus Infections

(2010) J. A. Olson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1->3)- -D-Glucan, and Consequences of Delayed Antifungal Therapy

(2010) W. W. Hope et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Single-Dose Liposomal Amphotericin B or Micafungin Prophylaxis in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

(2008) R. E. Lewis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changing epidemiology of systemic fungal infections

(2008) M. Richardson et al.   CLINICAL MICROBIOLOGY AND INFECTION